Followup of metastatic prostate cancer in remission – pro

Metasatic prostae cancer with no evidence of recurrence on or after ystemic treatmetn is more and more commonluy seen in clincal practice. There are no studies supporting routine imaging. NCCN(MS-16) recommends that clinical monitoring is determined by intensity of response to intial androgen deprivation, radiation or both. It mentions history and exam, digital rectal exam and PSA every 6 months. It does not recommend imaging., prostate cancer

A. Horwich, C. Parker1, C. Bangma2, V. Kataja and On behalf of the ESMO Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol (2010) 21 (suppl 5): v129-v133.

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal